Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23672161 | 1.00 | EZH2 (0.64) | EZH2KCNH2EZH1 | |
| SCHEMBL29965992 | 1.00 | EZH2 (0.64) | EZH2KCNH2EZH1 | |
| SCHEMBL16486389 | 0.93 | EZH2 (0.65) | EZH2KCNH2EZH1 | |
| SCHEMBL16486390 | 0.93 | EZH2 (0.65) | EZH2KCNH2EZH1 | |
| SCHEMBL16486192 | 0.90 | EZH2 (0.65) | EZH2KCNH2EZH1 | |
| SCHEMBL16486191 | 0.90 | EZH2 (0.65) | EZH2KCNH2EZH1 | |
| SCHEMBL29965628 | 0.90 | EZH2 (0.60) | EZH2KCNH2EZH1 | |
| SCHEMBL16486413 | 0.90 | EZH2 (0.60) | EZH2KCNH2EZH1 | |
| SCHEMBL16486410 | 0.90 | EZH2 (0.60) | EZH2KCNH2EZH1 | |
| SCHEMBL16486547 | 0.89 | EZH2 (0.54) | EZH2KCNH2EZH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210230148-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2021-07-29 | — | — | US | disclosed |
| US-10457640-B2 | Synthesis of inhibitors of EZH2 | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190233375-A1 | SYNTHESIS OF INHIBITORS OF EZH2 | CONSTELLATION PHARMACEUTICALS, INC. | 2019-08-01 | — | — | US | disclosed |
| CN-109843870-A | The synthesis of EZH2 inhibitor | 星座制药公司 | 2019-06-04 | — | — | CN | disclosed |
| WO-2018075598-A1 | SYNTHESIS OF INHIBITORS OF EZH2 | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457640-B2 | Synthesis of inhibitors of EZH2 | EZH2, EED, SUZ12 | EZH2 1/4885KCNH2 4566/4885EZH1 4/4885 |
| US-20190233375-A1 | SYNTHESIS OF INHIBITORS OF EZH2 | EZH2, EED, SUZ12 | EZH2 1/4885KCNH2 4566/4885EZH1 4/4885 |
| US-20210230148-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TPMT, TET1, TET2 | EZH2 150/4885KCNH2 4159/4885EZH1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.